iseganan
Small moleculeexperimental
Clinical trial activity
2 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
2
Phase 4
0
Earliest trial started Dec 1, 2000 (NCT00022373)
Timeline
Indications
Mechanism of action
- Unspecified targetUnclear
unclear
Chemistry & pharmacology
Loading structure…
SMILES
CC(C)C[C@H](NC(=O)CNC(=O)CNC(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@H]1CSSC[C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(N)=O)C(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CSSC[C@H](NC(=O)[C@H](Cc3ccc(O)cc3)NC1=O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccccc1)C(=O)N2- Mol. weight
- 1900.33 g/mol
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2110753 ↗
- ChEMBLCHEMBL2105862 ↗
Also known as
- antimicrobial peptide ib-367
- ib-367
- ib-367-03
- ib-367-03
- iseganan
- iseganan
- iseganan
- iseganan
- iseganan hcl
- iseganan hcl
- iseganan hydrochloride
- iseganan hydrochloride
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00118781 | Phase 2/Phase 3 (Phase 3) | Sep 1, 2003 | IntraBiotics Pharmaceuticals, Washington University in St. Louis |
| NCT00022373 | Phase 3 | Dec 1, 2000 | National Cancer Institute (NCI), University of California, Los Angeles |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| IntraBiotics Pharmaceuticals | For profit | 1 | 1 | 1 | 2003 |
| National Cancer Institute (NCI) | Government | 1 | 1 | 1 | 2000 |
| University of California, Los Angeles | Academic/Hospital | 1 | 0 | 1 | 2000 |
| Washington University in St. Louis | Academic/Hospital | 1 | 0 | 1 | 2003 |
4 organizations
Page 1 / 1